← Leaderboards
Gaorav P. Gupta
Duke University
$5,181,151
Attributed
$6,025,214
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,025,214 · 7
By mechanism
R37$2,886,304 · 1
P01$1,237,390 · 2
U01$809,450 · 1
P50$688,525 · 1
R01$355,464 · 1
P30$48,081 · 1
Top collaborators
- Dan Gabriel Duda2 shared
- Dana Casey1 shared
- Bhisham Chera1 shared
- Alice Ho1 shared
- Natalia Issaeva1 shared
- Wendell G Yarbrough1 shared
Most similar at Duke University
Same institution · by research overlap
- Lee Zou$13,956,280
- David Reardon$8,732,934
- John H Sampson$43,413,436
- Cathrine Hoyo$22,947,053
- Susan Kay Murphy$5,567,828
Others in their field
Other Emerging Leaders on “Programs”
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$348,328,584
- Lynn Briscoe · Leidos Biomedical Research, Inc.$312,382,073
- Chanza Baytop · Westat, Inc.$271,217,917
Research focus
ProgramsGenomicsCellsMediatingOverexpressionDna Double Strand BreakGenomic InstabilityAllelesEngineeringTumorMalignant Breast NeoplasmBreastResponseChemotherapyMouse ModelPathway InteractionsDna DamageTriple-Negative Invasive Breast CarcinomaCancer TherapyMutationBreast Cancer ModelInsightErbb2 GeneMalignant Neoplasms
Grant awards (19)
Project 2: TMEJ Regulation in Cancer and Treatment Resistance$466,907
P01 · FY2025 · CA · contact PI
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis$422,092
R37 · FY2025 · CA · contact PI
Project 2: Determinants of Response and Resistance to DNA-Damaging Radiation Plus Immunotherapy Combinations in Triple Negative Breast Cancer$350,219
P50 · FY2025 · CA · contact PI
Breast Cancer Research Program$48,081
P30 · FY2025 · CA · contact PI
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis$400,986
R37 · FY2024 · CA · contact PI
Project 2: Determinants of Response and Resistance to DNA-Damaging Radiation Plus Immunotherapy Combinations in Triple Negative Breast Cancer$338,306
P50 · FY2024 · CA · contact PI
Cell line Core$143,963
P01 · FY2024 · CA · contact PI
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis$413,651
R37 · FY2023 · CA · contact PI
Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer$355,463
R01 · FY2023 · CA · contact PI
Cell line Core$153,254
P01 · FY2023 · CA · contact PI
Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer$1
R01 · FY2023 · CA
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis$422,092
R37 · FY2022 · CA · contact PI
Cell line Core$155,829
P01 · FY2022 · CA · contact PI
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis$409,161
R37 · FY2021 · CA · contact PI
Cell line Core$124,774
P01 · FY2021 · CA · contact PI
Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC$809,450
U01 · FY2020 · DE
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis$409,161
R37 · FY2020 · CA · contact PI
Cell line Core$192,663
P01 · FY2020 · CA · contact PI
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis$409,161
R37 · FY2019 · CA · contact PI